Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 16:05 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

today announced the launch of AdvanceAD-Tx™, a GEP test designed to guide systemic treatment decision making in patients ages 12 and older.